2.1
Pirtobrutinib (Jaypirca, Eli Lilly & Company) is indicated as monotherapy for 'the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) who have been previously treated with a BTK inhibitor'.
2 Information about pirtobrutinib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for pirtobrutinib.
Price
2.3
The list price for pirtobrutinib is £2,081.50 for a 28-pack of 50 mg tablets and £8,325.00 for a 56-pack of 100 mg tablets (excluding VAT; BNF online accessed June 2026).
2.4
The company has a commercial arrangement. This makes pirtobrutinib available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on Eli Lilly & Company's environmental sustainability webpage.